vs

Side-by-side financial comparison of NEKTAR THERAPEUTICS (NKTR) and Simulations Plus, Inc. (SLP). Click either name above to swap in a different company.

NEKTAR THERAPEUTICS is the larger business by last-quarter revenue ($21.8M vs $18.4M, roughly 1.2× Simulations Plus, Inc.). Simulations Plus, Inc. runs the higher net margin — 3.7% vs -165.4%, a 169.1% gap on every dollar of revenue. On growth, Simulations Plus, Inc. posted the faster year-over-year revenue change (-2.7% vs -25.3%). Over the past eight quarters, NEKTAR THERAPEUTICS's revenue compounded faster (0.4% CAGR vs 0.3%).

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...

Simulations Plus, Inc. develops absorption, distribution, metabolism, excretion, and toxicity (ADMET) modeling and simulation software for the pharmaceutical and biotechnology, industrial chemicals, cosmetics, food ingredients, and herbicide industries. In September 2014, the company acquired Cognigen Corporation, a provider of clinical trial data analysis and consulting services.

NKTR vs SLP — Head-to-Head

Bigger by revenue
NKTR
NKTR
1.2× larger
NKTR
$21.8M
$18.4M
SLP
Growing faster (revenue YoY)
SLP
SLP
+22.6% gap
SLP
-2.7%
-25.3%
NKTR
Higher net margin
SLP
SLP
169.1% more per $
SLP
3.7%
-165.4%
NKTR
Faster 2-yr revenue CAGR
NKTR
NKTR
Annualised
NKTR
0.4%
0.3%
SLP

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
NKTR
NKTR
SLP
SLP
Revenue
$21.8M
$18.4M
Net Profit
$-36.1M
$676.0K
Gross Margin
59.1%
Operating Margin
-126.9%
3.9%
Net Margin
-165.4%
3.7%
Revenue YoY
-25.3%
-2.7%
Net Profit YoY
-596.9%
228.2%
EPS (diluted)
$-4.67
$0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NKTR
NKTR
SLP
SLP
Q4 25
$21.8M
$18.4M
Q3 25
$11.8M
$17.5M
Q2 25
$11.2M
$20.4M
Q1 25
$10.5M
$22.4M
Q4 24
$29.2M
$18.9M
Q3 24
$24.1M
$18.7M
Q2 24
$23.5M
$18.5M
Q1 24
$21.6M
$18.3M
Net Profit
NKTR
NKTR
SLP
SLP
Q4 25
$-36.1M
$676.0K
Q3 25
$-35.5M
$-681.0K
Q2 25
$-41.6M
$-67.3M
Q1 25
$-50.9M
$3.1M
Q4 24
$7.3M
$206.0K
Q3 24
$-37.1M
$843.0K
Q2 24
$-52.4M
$3.1M
Q1 24
$-36.8M
$4.0M
Gross Margin
NKTR
NKTR
SLP
SLP
Q4 25
59.1%
Q3 25
56.4%
Q2 25
64.0%
Q1 25
58.5%
Q4 24
72.7%
54.0%
Q3 24
81.6%
36.6%
Q2 24
58.5%
71.5%
Q1 24
60.6%
72.2%
Operating Margin
NKTR
NKTR
SLP
SLP
Q4 25
-126.9%
3.9%
Q3 25
-268.6%
3.8%
Q2 25
-324.2%
-364.5%
Q1 25
-425.8%
12.1%
Q4 24
49.2%
0.7%
Q3 24
-142.4%
-6.2%
Q2 24
-211.9%
10.1%
Q1 24
-163.7%
24.3%
Net Margin
NKTR
NKTR
SLP
SLP
Q4 25
-165.4%
3.7%
Q3 25
-301.3%
-3.9%
Q2 25
-372.2%
-330.6%
Q1 25
-486.4%
13.7%
Q4 24
24.9%
1.1%
Q3 24
-153.6%
4.5%
Q2 24
-222.9%
16.9%
Q1 24
-170.1%
22.0%
EPS (diluted)
NKTR
NKTR
SLP
SLP
Q4 25
$-4.67
$0.03
Q3 25
$-1.87
$-0.03
Q2 25
$-2.95
$-3.35
Q1 25
$-0.24
$0.15
Q4 24
$-2.07
$0.01
Q3 24
$-2.66
$0.04
Q2 24
$-3.76
$0.15
Q1 24
$-0.19
$0.20

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NKTR
NKTR
SLP
SLP
Cash + ST InvestmentsLiquidity on hand
$15.1M
$35.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$89.8M
$127.1M
Total Assets
$280.4M
$137.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NKTR
NKTR
SLP
SLP
Q4 25
$15.1M
$35.7M
Q3 25
$41.0M
$32.4M
Q2 25
$43.0M
$28.4M
Q1 25
$38.9M
$21.4M
Q4 24
$44.3M
$18.2M
Q3 24
$30.1M
$20.3M
Q2 24
$27.9M
$119.0M
Q1 24
$48.6M
$108.5M
Stockholders' Equity
NKTR
NKTR
SLP
SLP
Q4 25
$89.8M
$127.1M
Q3 25
$85.1M
$124.8M
Q2 25
$-24.2M
$123.8M
Q1 25
$13.7M
$189.5M
Q4 24
$60.7M
$184.7M
Q3 24
$48.9M
$182.4M
Q2 24
$79.7M
$180.9M
Q1 24
$126.7M
$177.0M
Total Assets
NKTR
NKTR
SLP
SLP
Q4 25
$280.4M
$137.8M
Q3 25
$301.3M
$131.9M
Q2 25
$207.5M
$134.4M
Q1 25
$256.2M
$201.4M
Q4 24
$303.9M
$196.9M
Q3 24
$308.0M
$196.6M
Q2 24
$343.3M
$192.7M
Q1 24
$396.0M
$194.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NKTR
NKTR
SLP
SLP
Operating Cash FlowLast quarter
$-65.0M
$4.2M
Free Cash FlowOCF − Capex
$-65.0M
FCF MarginFCF / Revenue
-298.0%
Capex IntensityCapex / Revenue
0.1%
0.0%
Cash ConversionOCF / Net Profit
6.26×
TTM Free Cash FlowTrailing 4 quarters
$-208.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NKTR
NKTR
SLP
SLP
Q4 25
$-65.0M
$4.2M
Q3 25
$-48.8M
$5.6M
Q2 25
$-45.7M
$8.1M
Q1 25
$-49.1M
$5.7M
Q4 24
$-46.2M
$-1.3M
Q3 24
$-43.9M
$1.7M
Q2 24
$-37.7M
$5.7M
Q1 24
$-47.9M
$5.8M
Free Cash Flow
NKTR
NKTR
SLP
SLP
Q4 25
$-65.0M
Q3 25
$-48.9M
$5.3M
Q2 25
$-45.8M
$7.8M
Q1 25
$-49.1M
$5.6M
Q4 24
$-46.6M
$-1.4M
Q3 24
$-44.6M
$1.6M
Q2 24
$-37.9M
$5.6M
Q1 24
$-48.0M
$5.4M
FCF Margin
NKTR
NKTR
SLP
SLP
Q4 25
-298.0%
Q3 25
-414.5%
30.5%
Q2 25
-409.6%
38.5%
Q1 25
-469.0%
25.0%
Q4 24
-159.9%
-7.2%
Q3 24
-184.9%
8.8%
Q2 24
-161.3%
30.0%
Q1 24
-222.0%
29.4%
Capex Intensity
NKTR
NKTR
SLP
SLP
Q4 25
0.1%
0.0%
Q3 25
1.0%
1.5%
Q2 25
0.3%
1.5%
Q1 25
0.0%
0.3%
Q4 24
1.6%
0.5%
Q3 24
2.8%
0.1%
Q2 24
0.8%
0.6%
Q1 24
0.7%
2.4%
Cash Conversion
NKTR
NKTR
SLP
SLP
Q4 25
6.26×
Q3 25
Q2 25
Q1 25
1.84×
Q4 24
-6.36×
-6.18×
Q3 24
1.97×
Q2 24
1.81×
Q1 24
1.44×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NKTR
NKTR

Segment breakdown not available.

SLP
SLP

Services Segment$9.5M52%
Development$7.2M39%
Discovery$1.3M7%

Related Comparisons